ArticleClinicoEconomics and outcomes research : CEOR2026
Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While chemotherapy is the standard treatment for adults with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL), long-term remission remains difficult to achieve. Blinatumomab, an immunotherapy drug, has shown survival benefits when alternated with consolidation chemotherapy in patients with CD19-positive Ph- B-cell ALL, but its economic value had not been assessed in Italy. Methods: This study evaluated the cost-effectiveness of alternating blinatumomab with standard consolidation chemotherapy compared with chemotherapy alone, using data from the ECOG-ACRIN E1910 Phase III trial. A model was developed to estimate lifetime health outcomes and costs from the perspective of the Italian National Health Service. Results: Patients who received blinatumomab lived on average 5.06 years longer and gained 4.56 more quality-adjusted life years, but incurred higher healthcare costs, with an incremental cost of €165,401 per patient, primarily due to drug acquisition. The incremental cost-effectiveness ratio (ICER) was €36,261 per quality-adjusted life year gained, within the range of values typically considered acceptable in Italy. These results were confirmed in sensitivity analyses, with the ICER ranging from €28,082 to €49,034 under various assumptions. Conclusion: The alternation of blinatumomab with chemotherapy provides a substantial clinical benefit at a cost that is likely acceptable to the Italian healthcare system. These findings support the value of blinatumomab in improving outcomes in adult patients newly diagnosed with Ph- CD19-positive B-cell ALL. Results were consistent across sensitivity analyses, supporting the robustness of the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.